Alpha-9 Theranostics Announces Oversubscribed $75 Million Series B Financing To Advance Portfolio Of Radiopharmaceuticals For Cancer
Amount Raised
$75 Million
Round Type
Series B
BostonBiotechnologyHealth CareTherapeuticsBiopharmaInvestors
Description
Alpha-9 Theranostics Inc., a clinical stage company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer, today announced an oversubscribed $75 million Series B financing. The round was led by Nextech Invest, with participation from Frazier Life Sciences, Samsara BioCapital and Quark Venture in addition to existing investors Longitude Capital and BVF Partners.
Quick answer
Alpha-9 Theranostics raised $75 Million in a Series B round, dated December 14, 2022. Investors: BVF Partners, Longitude Capital, Quark Venture and Samsara Bio Capital. Alpha-9 Theranostics is based in Boston, Massachusetts, United States.
- How much did Alpha-9 Theranostics raise?
- Alpha-9 Theranostics raised $75 Million in a Series B round on December 14, 2022.
- Who invested in Alpha-9 Theranostics?
- BVF Partners, Longitude Capital, Quark Venture and Samsara Bio Capital are named as investors in this round.
- What does Alpha-9 Theranostics do?
- Alpha-9 Theranostics is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with..
- Where is Alpha-9 Theranostics based and how big is it?
- Alpha-9 Theranostics is based in Boston, Massachusetts, United States. Fundz records about 47 employees.
- Who are the decision-makers at Alpha-9 Theranostics?
- Fundz holds 3 contacts at Alpha-9 Theranostics, including the CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biopharma around the same time
Companies in the same sectors as Alpha-9 Theranostics that raised within 45 days of this round, from Fundz verified event records.
- HighTide Therapeutics raised $107M (Series C) on January 5, 2023.
- GenSight Biologics raised $13M (Convertible Note) on December 23, 2022.
- Madrigal Pharmaceuticals raised $300M (Funding Round) on December 21, 2022.
- Opna Bio raised $38M (Series A) on November 21, 2022.
- Parabilis Medicines raised $178M (Series D) on November 21, 2022.
- Parabilis Medicines raised $178M on November 17, 2022.
Who to call at Alpha-9 Theranostics, and when
A new round usually means Alpha-9 Theranostics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Alpha-9 Theranostics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Alpha-9 Theranostics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alpha-9 Theranostics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alpha-9 Theranostics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAlpha-9 Theranostics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.